To date, the discussion is still ongoing whether the Siewert II adenocarcinoma of the esophagogastric junction (AEG) should be resected either by thoracoabdominal esophagectomy or gastrectomy with resection of the distal esophagus by transhiatal extension. The aim of our study was to compare the oncological and perioperative outcomes of the transthoracic approach (TTA) and the transabdominal approach (TAA).
Methods
Searches of electronic databases identifying studies from Cochrane, PubMed and Google Scholar were performed. Randomised and non-randomised studies comparing TTA and TAA approaches for surgical treatment of AEG Siewert type II were included. The Newcastle–Ottawa and Jada scales were used to evaluate methodological quality. The risk of bias was assessed using the Rob v2 and Robins-I tools. Meta-analyses were conducted for the outcomes.
Results
We included 17 trials (2 randomised controlled trials and 15 cohorts) involving 15297 patients. Longer three-year overall survival, five-year overall survival and R0 resection rates were observed in the TTA group. However, TTA had greater morbidity and pulmonary complications.
Conclusion
Transthoracic approach appears to be preferable for selected Siewert II tumours. This may lead to higher survival rates and better R0 resection rate. Well-designed studies are needed to confirm the results of this systematic review.
TsengJPosnerMC. For gastroesophageal junction cancers, does an “esophageal” or “gastric”. Surgical approach offer better perioperative and oncologic outcomes?. Ann Surg Oncol2020; 27: 511–517.
4.
SiewertJHölscherABeckerK,et al.Cardia cancer: attempt at a therapeutically relevant classification. Chirurg1987; 58: 25–32.
5.
SiewertJSteinHFeithM. Adenocarcinoma of the esophago-gastric junction. Scand J Surg2006; 95: 260–269.
6.
KumamotoTKurahashiYNiwaH, et al.True esophagogastric junction adenocarcinoma: background of its definition and current surgical trends. Surg Today2019; 50: 809–814.
7.
BlankSSchmidtTHegerP, et al.Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach?Gastric Cancer2018; 21: 303–314.
8.
VoronTGronnierCPasquerA, et al.Adenocarcinoma of the oesophagogastric junction siewert II: an oesophageal cancer better cured with total gastrectomy. Eur J Surg Oncol2019; 45: 2473–2481.
9.
HigginsJPThomasJChandlerJ, et al.Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons, 2019.
10.
SterneJASavovićJPageMJ, et al.Rob 2: a revised tool for assessing risk of bias in randomised trials. Br Med J2019; 366: l4898.
11.
SterneJAHernánMAReevesBC, et al.ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. Br Med J2016; 355: i4919.
12.
McGuinnessLAHigginsJP. Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments. Res Synth Methods2021; 12: 55–61.
13.
BarbourAPRizkNPGonenM, et al.Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome. Ann Surg2007; 246: 1.
14.
CelikuEDraciniXDibraA,et al.Surgical treatment of the adenocarcinoma of the cardia. G Chir2011; 32: 353–356.
15.
DayRWBadgwellBDFournierKF, et al.Defining the impact of surgical approach on perioperative outcomes for patients with gastric cardia malignancy. J Gastrointest Surg2016; 20: 146–153.
16.
ItoHClancyTEOsteenRT, et al.Adenocarcinoma of the gastric cardia: what is the optimal surgical approach?J Am Coll Surg2004; 199: 880–886.
17.
JohanssonJDjerfPÖbergS, et al.Two different surgical approaches in the treatment of adenocarcinoma at the gastroesophageal junction. World J Surg2008; 32: 1013–1020.
18.
KimKTJeongOJungMR, et al.Outcomes of abdominal total gastrectomy for type II and III gastroesophageal junction tumors: single center's experience in Korea. J Gastric Cancer2012; 12: 36–42.
19.
KauppilaJHRingborgCJoharA, et al.Health-related quality of life after gastrectomy, esophagectomy, and combined esophagogastrectomy for gastroesophageal junction adenocarcinoma. Gastric Cancer2018; 21: 533–541.
20.
KauppilaJHWahlinKLagergrenJ. Gastrectomy compared to oesophagectomy for siewert II and III gastro-oesophageal junctional cancer in relation to resection margins, lymphadenectomy and survival. Sci Rep2017; 7: 1–6.
21.
MarietteCCastelBTourselH, et al.Surgical management of and long-term survival after adenocarcinoma of the cardia. Br J Surg2002; 89: 1156–1163.
22.
MattioliSDi SimoneMFerruzziL, et al.Surgical therapy for adenocarcinoma of the cardia: modalities of recurrence and extension of resection. Dis Esophagus2001; 14: 104–109.
23.
ReehMMinaSBockhornM, et al.Staging and outcome depending on surgical treatment in adenocarcinomas of the oesophagogastric junction. Br J Surg2012; 99: 1406–1414.
24.
SasakoMSanoTYamamotoS, et al.Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol2006; 7: 644–651.
25.
SchumacherGSchmidtSSchlechtwegN, et al.Surgical results of patients after esophageal resection or extended gastrectomy for cancer of the esophagogastric junction. Dis Esophagus2009; 22: 422–426.
26.
HolguinRAPWongWGShenC, et al.Esophagectomy vs gastrectomy for early stage adenocarcinoma of the gastroesophageal junction: What is the optimal oncologic surgical treatment?Semin Thorac Cardiovasc Surg2022; 35: 807–819.
27.
MertensACKalffMCEshuisWJ, et al.Transthoracic versus transhiatal esophagectomy for esophageal cancer: a nationwide propensity score-matched cohort analysis. Ann Surg Oncol2021; 28: 175–183.
28.
ZhaoBZhangZMoD, et al.Optimal extent of transhiatal gastrectomy and lymphadenectomy for the stomach-predominant adenocarcinoma of esophagogastric junction: retrospective single-institution study in China. Front Oncol2019; 8: 639.
29.
TaoKDongJHeS, et al.Surgical strategies for siewert type II esophagogastric junction carcinomas: a randomized controlled trial. Front Oncol2022; 12: 852594.
30.
VoronTGronnierCPasquerA, et al.Adenocarcinoma of the oesophagogastric junction siewert II: an oesophageal cancer better cured with total gastrectomy. Eur J Surg Oncol2019; 45: 2473–2481.
31.
MartinJTMahanAZwischenbergerJB, et al.Should gastric cardia cancers be treated with esophagectomy or total gastrectomy? A comprehensive analysis of 4,996 NSQIP/SEER patients. J Am Coll Surg2015; 220: 510–520.
32.
GuanGJiangWLiuX, et al.Effects of different surgical approaches on Siewert II adenocarcinoma of esophagogastric junction. Chin J Gen Surg2011; 12: 721–725.
33.
StürzlRGerkenMBrunsC, et al.Chirurgische therapie des adenokarzinoms des ösophagogastralen Übergangs typ II. Die Chirurgie2022; 93: 1072–1081.
34.
YangSYuanYHuH, et al.Survival comparison of Siewert II adenocarcinoma of esophagogastric junction between transthoracic and transabdominal approaches: a joint data analysis of thoracic and gastrointestinal surgery. Zhonghua Wei Chang Wai Ke Za Zhi2019; 22: 132–142.
35.
ReddavidRStrignanoPSofiaS, et al.Transhiatal distal esophagectomy for Siewert type II cardia cancer can be a treatment option in selected patients. Eur J Surg Oncol2019; 45: 1943–1949.
36.
TosoliniCReimDSchirrenR, et al.Influence of the surgical technique on survival in the treatment of carcinomas of the true cardia (siewert type II)-right thoracoabdominal vs. transhiatal-abdominal approach. Eur J Surg Oncol2019; 45: 416–424.
37.
ChenYZhaoXKXuRH, et al.Transthoracic, thoracoabdominal, and transabdominal surgical approaches for gastric cardia adenocarcinomas: a survival evaluation based on a cohort of 7103 patients. World J Surg Oncol2022; 20: 1–10.
38.
De PasqualCAvan der SluisPCWeindelmayerJ, et al.Transthoracic esophagectomy compared to transhiatal extended gastrectomy for adenocarcinoma of the esophagogastric junction: a multicenter retrospective cohort study. Dis Esophagus2022; 35: doab090.
39.
JunttilaAHelminenOHelmiöM, et al.Long-term survival after transhiatal versus transthoracic esophagectomy: a population-based nationwide study in Finland. Ann Surg Oncol2022; 29: 8158–8167.
40.
KamarajahSKPhillipsAWGriffithsEA, et al.Esophagectomy or total gastrectomy for Siewert 2 gastroesophageal junction (GEJ) adenocarcinoma? A registry-based analysis. Ann Surg Oncol2021; 28: 8485–8494.
41.
KurokawaYSasakoMSanoT, et al.Ten-year follow-up results of a randomized clinical trial comparing left thoracoabdominal and abdominal transhiatal approaches to total gastrectomy for adenocarcinoma of the oesophagogastric junction or gastric cardia. Br J Surg2015; 102: 341.
42.
LiHZhuXZhouX,et al.Transthoracic Approach vs Transhiatal-Abdominal Approach in the Treatment of Locally Advanced Siewert Type II Esophagogastric Junctional Adenocarcinoma: A Retrospective Study. 2021.
43.
MineSKurokawaYTakeuchiH, et al.Postoperative complications after a transthoracic esophagectomy or a transhiatal gastrectomy in patients with esophagogastric junctional cancers: a prospective nationwide multicenter study. Gastric Cancer2021; 25: 430–437.
44.
OhSELeeGHAnJY, et al.Comparison of transabdominal and transthoracic surgical approaches in the treatment of Siewert type II esophagogastric junction cancers: a propensity score-matching analysis. Eur J Surg Oncol2022; 48: 370–376.
45.
OmlooJMLagardeSMHulscherJB, et al.Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg2007; 246: 992–1001.
46.
XingJLiuMXuK, et al.Short-term and long-term outcomes following transhiatal versus right thoracoabdominal resection of Siewert type II adenocarcinoma of the esophagogastric junction. Cancer Manag Res2020; 12: 11813.
47.
YangZ-FWuD-QWangJ-J, et al.Surgical approach for Siewert type II adenocarcinoma of the esophagogastric junction: transthoracic or transabdominal? – a single-center retrospective study. Ann Transl Med2018; 6.
48.
ZhuKXuYFuJ, et al.Proximal gastrectomy versus total gastrectomy for Siewert type II adenocarcinoma of the esophagogastric junction: a comprehensive analysis of data from the SEER registry. Dis Markers2019; 2019: 9637972.
49.
ZhengBChenYHuY, et al.Comparison of transthoracic and transabdominal surgical approaches for the treatment of adenocarcinoma of the cardia. Chin J Cancer2010; 29: 747–751.
50.
WuHShangLDuF, et al.Transhiatal versus transthoracic surgical approach for siewert type II adenocarcinoma of the esophagogastric junction: a meta-analysis. Expert Rev Gastroenterol Hepatol2020; 14: 1107–1117.
51.
MaatoukMBen SaftaYKbirGH, et al.Can we predict mediastinal lymph nodes metastasis in esophagogastric junction cancer? Results of a systematic review and meta-analysis. Gen Thorac Cardiovasc Surg2021; 69: 1165–1173.
52.
de GrootEGoenseLKingmaB, et al.Trends in surgical techniques for the treatment of esophageal and gastroesophageal junction cancer: the 2022 update. Dis Esophagus2023; 36.
53.
HaverkampLSeesingMRuurdaJ, et al.Worldwide trends in surgical techniques in the treatment of esophageal and gastroesophageal junction cancer. Dis Esophagus2017; 30: 1–7.
54.
SobinLHGospodarowiczMKWittekindC. TNM Classification of Malignant Tumours. John Wiley & Sons, 2011.
55.
BrierleyJGospodarowiczMWittekindC. TNM Classification of Malignant Tumours. Hoboken, NJ, USA: JohnWiley & Sons Inc, 2017.
56.
jp JGCAjkk-ma. Japanese Gastric cancer treatment guidelines 2021. Gastric Cancer2023; 26: 1–25.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
